Our Approach

Ardelyx develops:

  • Innovative, non-systemic, small molecule therapeutics that work exclusively in the GI tract to treat cardio-renal, GI and metabolic diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Therapeutic Areas

We are developing our lead product candidate, tenapanor, for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and for the treatment of hyperphosphatemia in dialysis patients with end-stage renal disease. We are also developing RDX022 for the treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.Through our collaboration partner, Sanofi, we are also continuing discovery efforts with our NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD patients. Ardelyx is also independently advancing several research programs focused in cardio-renal, gastrointestinal and metabolic diseases.